Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease patients

References

[1] Vuppalanchi R,Alkhouri N.Therapeutic pipeline in nonalcoholic steatohepatitis.Nat Rev Gastroenterol Hepatol2021;18:373-92

[2] Kulik L.Epidemiology and management of hepatocellular carcinoma.Gastroenterology2019;156:477-491.e1 PMCID:PMC6340716

[3] Ioannou GN.Epidemiology and risk-stratification of NAFLD-associated HCC.J Hepatol2021;75:1476-84

[4] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-1837.e2 PMCID:PMC6279617

[5] Orci LA,Caballol B.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.Clin Gastroenterol Hepatol2022;20:283-292.e10

[6] Younossi Z,Ong JP.Global nonalcoholic steatohepatitis council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.Clin Gastroenterol Hepatol2019;17:748-755.e3

[7] Noureddin M,Bresee C.NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances.Am J Gastroenterol2018;113:1649-59 PMCID:PMC9083888

[8] Wong RJ,Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology2014;59:2188-95

[9] Yatsuji S,Tobari M,Tokushige K.Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.J Gastroenterol Hepatol2009;24:248-54

[10] Ioannou GN,Lowy E,Berry K.Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.PLoS One2018;13:e0204412 PMCID:PMC6160079

[11] Gawrieh S,Miller E.Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.Aliment Pharmacol Ther2019;50:809-21

[12] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[13] Tan DJH,Lin SY.Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.Lancet Oncol2022;23:521-30

[14] Adams LA,St Sauver J.The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology2005;129:113-21

[15] White DL,El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Clin Gastroenterol Hepatol2012;10:1342-1359.e2 PMCID:PMC3501546

[16] Noureddin M.Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.Clin Liver Dis2015;19:361-79 PMCID:PMC6658171

[17] Zelber-Sagi S,Shibolet O.Lifestyle and hepatocellular carcinoma what is the evidence and prevention recommendations.Cancers (Basel)2021;14:103 PMCID:PMC8750465

[18] Younes R.NASH in lean individuals.Semin Liver Dis2019;39:86-95

[19] Aby E,Truong E,Saab S.Inadequate hepatocellular carcinoma screening in patients with nonalcoholic steatohepatitis cirrhosis.J Clin Gastroenterol2019;53:142-6

[20] Mittal S,El-Serag HB.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.Clin Gastroenterol Hepatol2015;13:594-601.e1 PMCID:PMC4333060

[21] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.Hepatology2018;68:723-50

[22] Association for the Study of the Liver; Electronic address: [e-mail].; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[23] Loomba R,Patton H.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.Gastroenterology2020;158:1822-30 PMCID:PMC8012107

[24] Noureddin M,Alkhouri N,Dieterich DT.NASHNETScreening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the united states is cost-effective: a comprehensive cost-utility analysis.Gastroenterology2020;159:1985-1987.e4

[25] Lewis CM.Polygenic risk scores: from research tools to clinical instruments.Genome Med2020;12:44 PMCID:PMC7236300

[26] Singal AG,Yopp AC.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.Am J Gastroenterol2014;109:325-34 PMCID:PMC5610907

[27] Liu YL,Leathart JB.Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.J Hepatol2014;61:75-81

[28] Krawczyk M,Romeo S.HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.J Hepatol2015;62:980-1

[29] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554

[30] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[31] Tobkes AI.Liver biopsy: review of methodology and complications.Dig Dis1995;13:267-74

[32] Saleh HA.Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis.J Gastrointestin Liver Dis2007;16:425-6

[33] Guha IN,Roderick P.Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers.Hepatology2008;47:455-60

[34] Sanyal AJFriedman SLMcCullough AJDimick-Santos LAmerican Association for the Study of Liver DiseasesChallenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American association for the study of liver diseases-U.S. Food and Drug Administration joint workshop.Hepatology2015;61:1392-405 PMCID:PMC4900161

[35] Angulo P,Marchesini G.The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology2007;45:846-54

[36] Hsu C,Imajo K.Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants.Clin Gastroenterol Hepatol2019;17:630-637.e8 PMCID:PMC6294709

[37] Mayo R,Martínez-Arranz I.Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts.Hepatol Commun2018;2:807-20 PMCID:PMC6049064

[38] Younossi ZM,Newsome PN. Agile 3+ development and validation: novel fibroscan based score to diagnose advanced fibrosis in non alcoholic fatty liver disease patients. Available from: https://www.postersessiononline.eu/173580348_eu/congresos/NAFLDsummit/aula/-PO_157_NAFLDsummit.pdf [Last accessed on 7 Nov 2022]

[39] Younossi ZM,Newsome PN. LP12-improving diagnosis of cirrhosis in patients with NAFLD by combining liver stiffness measurement by vibration-controlled transient elastography and routine biomarkers: a global derivation and validation study. Available from: https://aasld.confex.com/aasld/2020/meetingapp.cgi/Paper/24427 [Last accessed on 7 Nov 2022]

[40] Xiao G,Xiao X,Yang J.Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis.Hepatology2017;66:1486-501

[41] Ampuero J,Aller R.HEPAmet Registry. Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis.Clin Gastroenterol Hepatol2020;18:216-225.e5

[42] Jung J,Imajo K.MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.Gut2021;70:1946-53 PMCID:PMC8131405

[43] Noureddin M,Gornbein JA.MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.J Hepatol2022;76:781-7

[44] Younossi ZM,Bernstein D.Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations.Am J Gastroenterol2021;116:254-62

[45] Younes R,Govaere O.Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.J Hepatol2021;75:786-94

[46] Tzartzeva K,Rich NE.Surveillance imaging and Alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-1718.e1 PMCID:PMC5927818

[47] Rich N.Hepatocellular carcinoma tumour markers: current role and expectations.Best Pract Res Clin Gastroenterol2014;28:843-53

[48] Ye Q,Zheng S.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Mol Cancer2019;18:114 PMCID:PMC6607541

[49] Ahn JC,Chen PJ.Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma.Hepatology2021;73:422-36 PMCID:PMC8183673

[50] Yang JD,Mara KC.GALAD Score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score.Cancer Epidemiol Biomarkers Prev2019;28:531-8 PMCID:PMC6401221

[51] Del Poggio P,Ciccarese F.Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2014;12:1927-33.e2

[52] Simmons O,Yokoo T.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[53] Younes R.Should we undertake surveillance for HCC in patients with NAFLD?.J Hepatol2018;68:326-34

[54] Schoenberger H,Fetzer DT.Dynamic changes in ultrasound quality for hepatocellular carcinoma screening in patients with cirrhosis.Clin Gastroenterol Hepatol2022;20:1561-1569.e4 PMCID:PMC8660956

[55] Atiq O,Yopp AC.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis.Hepatology2017;65:1196-205 PMCID:PMC5659110

[56] Morgan TA,Dahiya N,Kamaya A.US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma.Abdom Radiol (NY)2018;43:41-55

[57] Chernyak V,Kamaya A.Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients.Radiology2018;289:816-30 PMCID:PMC6677371